Spontaneous Bacterial Peritonitis (SBP)

Cloudy abdominal fluid and its cultured bacteria
Cloudy abdominal fluid and its cultured bacteria

Spontaneous bacterial peritonitis (SBP) is a life-threatening infection of ascitic fluid that occurs without an obvious surgically correctable source, such as a perforated bowel. It is a defining complication of decompensated cirrhosis — arising in 10–30% of hospitalized cirrhotics with ascites — and carries an in-hospital mortality of 20–30% even with prompt treatment. The name "spontaneous" distinguishes it from secondary bacterial peritonitis (caused by intra-abdominal pathology), but it is anything but spontaneous: it is the predictable result of gut bacterial translocation into a peritoneal fluid that lacks the immune defenses needed to clear an infection.

  1. Overview and Epidemiology
  2. Pathophysiology: Bacterial Translocation
  3. Causative Organisms
  4. Clinical Presentation
  5. Diagnosis: The Diagnostic Paracentesis
  6. Distinguishing Secondary Bacterial Peritonitis
  7. Treatment
  8. Albumin Infusion: Preventing Kidney Injury
  9. Prophylaxis and Prevention
  10. Prognosis and Long-Term Outlook
  11. Key Research Papers
  12. Connections

Overview and Epidemiology

SBP occurs almost exclusively in patients with cirrhosis and ascites — the portal hypertension-driven accumulation of fluid in the peritoneal cavity. It is rare in other causes of ascites (e.g., heart failure, cancer) because the ascitic protein and complement levels in those conditions are typically higher, providing some immune barrier. In cirrhotic ascites, total protein is often below 15 g/L, and levels of complement C3 and opsonins are severely reduced, leaving the fluid defenseless against bacteria that translocate from the gut.

The annual incidence of SBP in outpatients with cirrhosis and ascites is 1.5–3.5%, rising sharply to 10–30% in hospitalized patients. The 1-year recurrence rate after a first episode of SBP, without prophylaxis, exceeds 40–70%. One-year mortality after a first SBP episode is approximately 30–50%, reflecting the severity of the underlying liver disease — SBP marks a transition to late-stage decompensated cirrhosis.

Risk factors for SBP include: low ascitic fluid total protein (<15 g/L), prior episode of SBP, acute gastrointestinal hemorrhage, Child-Pugh class C, serum bilirubin >3 mg/dL, and renal impairment.

Stomach-acid-lowering drugs (proton pump inhibitors) have also been linked to SBP. A 2021 meta-analysis of 23 studies and 10,386 patients found a pooled odds ratio of 1.80, weaker at 1.55 in cohort studies, with substantial differences between studies and signs of publication bias; its authors describe the association as weak.

Back to Table of Contents

Pathophysiology: Bacterial Translocation

SBP develops through a three-step cascade: bacterial translocation → bacteremia → peritoneal infection.

Step 1 — Gut bacterial overgrowth and translocation: Cirrhosis alters gut motility, increases intestinal permeability ("leaky gut"), and disrupts the mucosal immune barrier. Intestinal bacterial overgrowth (small intestinal bacterial overgrowth, SIBO) is common. Bacteria — predominantly enteric gram-negatives — breach the intestinal epithelium and enter mesenteric lymph nodes. In a healthy liver, the reticuloendothelial system (Kupffer cells) would clear these organisms from portal blood. In cirrhosis, Kupffer cell function is impaired and portosystemic shunting bypasses the hepatic filter entirely, allowing bacteremic spillover into systemic circulation.

Step 2 — Bacteremia: Transient or sustained bacteremia seeds the peritoneal fluid. The route is hematogenous, not direct spread from bowel.

Step 3 — Failure of peritoneal host defense: Cirrhotic ascitic fluid has critically low opsonic activity. Complement C3 levels in ascites correlate inversely with SBP risk — patients with ascitic C3 below 13 mg/dL have a dramatically higher rate of infection. Without opsonization, neutrophils cannot effectively phagocytose and kill bacteria. The infection amplifies unchecked, triggering a systemic inflammatory response that precipitates acute kidney injury (hepatorenal physiology) and worsens hepatic encephalopathy.

Why albumin infusion works: Albumin is not just a volume expander. It binds bacterial lipopolysaccharide (LPS) and other inflammatory mediators, modulates systemic vasodilation, and directly supports renal perfusion. This mechanism underpins why albumin co-administration with antibiotics reduces mortality — the antibiotic kills the bacteria but the inflammatory cascade from lipopolysaccharide release still harms the kidneys without albumin buffering.

Back to Table of Contents

Causative Organisms

SBP is predominantly caused by enteric organisms reflecting the gut-translocation route. Approximately 70% of SBP cases involve gram-negative bacilli:

Cultures are negative in approximately 40% of cases despite the ascitic neutrophil count meeting diagnostic criteria — these cases are called "culture-negative neutrocytic ascites" (CNNA) and carry the same prognosis and treatment as culture-positive SBP. Inoculating ascitic fluid directly into blood culture bottles at bedside (10 mL per bottle) significantly improves culture yield compared to sending fluid to the lab in sterile tubes.

Multidrug-resistant (MDR) organisms: MDR-SBP is an emerging problem, particularly in patients with prior antibiotic exposure, healthcare-associated infections, or who live in regions with high MDR prevalence. Third-generation cephalosporins (cefotaxime/ceftriaxone) have an 85–90% success rate in community-acquired SBP; MDR organisms require carbapenem therapy.

Back to Table of Contents

Clinical Presentation

The classic triad — fever, abdominal pain, and altered mental status — occurs in fewer than 50% of patients with SBP. Many patients, especially those with severe liver disease and hepatic encephalopathy as a baseline, present atypically or are entirely asymptomatic, discovered only because a diagnostic paracentesis is performed as standard of care.

Symptoms and signs when present:

What liver-society guidelines state: Guidelines call for diagnostic paracentesis in every person with cirrhosis admitted to hospital with ascites, regardless of symptoms, and whenever any clinical deterioration occurs (new encephalopathy, fever, abdominal pain, rising creatinine, or leukocytosis). Waiting for symptoms leads to delayed diagnosis and increased mortality.

In a two-center study of 239 hospital patients with SBP, those whose fluid was sampled 12 to 72 hours after admission died in hospital more often than those sampled within 12 hours (27% vs. 13%). Each hour of delay was associated with a 3.3% rise in in-hospital deaths after adjusting for the Model for End-Stage Liver Disease (MELD) score and creatinine.

Back to Table of Contents

Diagnosis: The Diagnostic Paracentesis

SBP is diagnosed by analysis of ascitic fluid obtained by paracentesis. The key diagnostic value is the ascitic fluid polymorphonuclear leukocyte (PMN) count — not the culture result.

SBP diagnostic criteria:

Ascitic fluid appearance: typically cloudy in SBP; turbid to frankly purulent in secondary peritonitis. Bloody ascites (traumatic tap or hepatocellular carcinoma, a liver cancer) requires correcting the PMN count: subtract 1 PMN per 250 red blood cells.

Additional ascitic fluid tests:

Point-of-care PMN testing: Reagent strip (leukocyte esterase dipstick) testing of ascitic fluid provides a rapid bedside PMN estimate, but its accuracy varies widely. A systematic review of 17 studies found sensitivity ranging from 45% to 100%, specificity from 81% to 100%, positive predictive value from 42% to 100% and negative predictive value from 87% to 100%, too inconsistent to pool. A multicenter study of 2,123 paracenteses found 45.3% sensitivity at a 2+ threshold and concluded that the strip it tested had no diagnostic efficacy. An emergency department study at a “trace” threshold found 95% sensitivity, 48% specificity and an 11% positive predictive value, and its authors could not recommend the strip as a stand-alone test.

Back to Table of Contents

Distinguishing Secondary Bacterial Peritonitis

Secondary bacterial peritonitis — peritoneal infection due to a surgically correctable intra-abdominal source (perforated viscus, abscess, cholecystitis) — is distinguished from SBP because its management is surgical, not antibiotic alone. Failure to recognize secondary peritonitis and operating on a patient believed to have SBP (or vice versa) carries high mortality.

Runyon's criteria for secondary peritonitis (any 2 of 3):

Additional features favoring secondary peritonitis: polymicrobial culture (multiple organisms), anaerobes or fungi on culture, very high PMN count (>5000/μL), loculated fluid on imaging, and failure to respond to appropriate antibiotics within 48 hours. Computed tomography (CT) of the abdomen is the urgent test used to identify the source when secondary peritonitis is suspected.

A repeat paracentesis at 48 hours is recommended in all SBP cases both to confirm treatment response (a PMN fall of >25% from baseline is the expected response) and to detect secondary peritonitis that was not initially apparent.

Back to Table of Contents

Treatment

Treatment of SBP has three pillars: antibiotics, albumin infusion, and identification/treatment of precipitants.

Antibiotics — first-line:

Infection acquired in hospital: In a small randomized trial of 31 analyzed patients with SBP acquired in hospital, meropenem plus daptomycin resolved the infection in 86.7% against 25% for ceftazidime, though 90-day transplant-free survival did not differ significantly between the groups.

Antibiotic de-escalation: Once culture results return with sensitivities, treatment is narrowed to the narrowest appropriate agent. For pneumococcal SBP (gram-positive), amoxicillin-clavulanate or ampicillin can replace the cephalosporin.

Monitoring response:

Back to Table of Contents

Albumin Infusion: Preventing Kidney Injury

Co-administration of intravenous albumin with antibiotics is the single most important advance in SBP management since the introduction of third-generation cephalosporins. The landmark Sort et al. 1999 NEJM trial established this standard of care.

The Sort trial (NEJM 1999): 126 cirrhotic patients with SBP randomized to cefotaxime alone vs. cefotaxime + albumin (1.5 g/kg intravenous on day 1, then 1 g/kg intravenous on day 3). Results:

Current recommendation (European Association for the Study of the Liver, American Association for the Study of Liver Diseases, Asian Pacific Association for the Study of the Liver):

Mechanism: Albumin reduces systemic inflammation (lipopolysaccharide binding), improves circulatory dysfunction (oncotic pressure supports splanchnic vasoconstriction), and attenuates the hepatorenal syndrome (HRS) cascade. SBP-precipitated HRS carries >50% 30-day mortality — albumin significantly reduces this complication.

Back to Table of Contents

Prophylaxis and Prevention

Given the 40–70% 1-year recurrence rate after a first SBP episode and the high associated mortality, guidelines recommend antibiotic prophylaxis in several high-risk settings.

How strong the evidence is: A 2020 Cochrane network meta-analysis (29 trials, 3,896 people) rated the evidence low or very low certainty and reported considerable uncertainty about whether antibiotic prophylaxis helps and, if it does, which antibiotic helps most. In a 2018 French trial of 291 people with Child-Pugh class C cirrhosis, norfloxacin did not lower 6-month deaths in the main analysis (14.8% vs. 19.7% on placebo, P = .21), though it appeared to improve survival in those with ascitic protein below 15 g/L.

Secondary prophylaxis (after a first SBP episode):

Primary prophylaxis — acute gastrointestinal hemorrhage:

Primary prophylaxis — low ascitic protein + severe liver disease:

Liver transplantation: Definitive treatment for the underlying cirrhosis. SBP is a complication that raises the Model for End-Stage Liver Disease (MELD) score and can accelerate transplant listing eligibility. Survival after SBP is commonly treated as a reason for urgent evaluation for transplant listing.

Back to Table of Contents

Prognosis and Long-Term Outlook

SBP is a sentinel event in the natural history of cirrhosis, marking the onset or acceleration of liver decompensation. Even when the infection resolves with antibiotics, the underlying circulatory dysfunction and portal hypertension that enabled SBP remain — setting the stage for recurrence and further complications.

In-hospital outcomes:

Long-term outcomes:

Predictors of poor prognosis: MELD score >20 at time of SBP, development of acute kidney injury, serum creatinine >3 mg/dL at diagnosis, hepatic encephalopathy grade III–IV, bacteremia (positive blood cultures), and MDR organisms.

A first episode of SBP is commonly treated as a reason for urgent referral to a liver transplant center if the person is not already under transplant evaluation. For patients who are not transplant candidates, the focus shifts to maximizing quality of remaining life — optimizing encephalopathy management, continuing prophylaxis, and counseling about goals of care.

Back to Table of Contents

Key Research Papers

  1. — Sort P et al. "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis." New England Journal of Medicine 1999. — PubMed PMID: 10432325 (The landmark trial establishing albumin co-administration; reduced renal impairment from 33% to 10% and in-hospital mortality from 29% to 10%.)
  2. — Gines P et al. "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial." Hepatology 1990. — PubMed PMID: 2210673 (Secondary prophylaxis trial; norfloxacin reduced 1-year recurrence from 68% to 20%.)
  3. — Fernandez J et al. "Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis." Gastroenterology 2007. — PubMed PMID: 17854593 (Norfloxacin primary prophylaxis; reduced SBP from 61% to 7% at 1 year.)
  4. — Rimola A et al. "Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club." Journal of Hepatology 2000. — PubMed PMID: 10673079 (Classic International Ascites Club consensus establishing 5-day cefotaxime as standard of care.)
  5. — Praharaj DL et al. "Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial." Journal of Clinical and Experimental Hepatology 2022. — PubMed PMID: 35535057 (Open-label trial; secondary prophylaxis recurrence 7% vs. 39%.)
  6. — Sidhu GS et al. "Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review." BMJ Open Gastroenterology 2017. — PubMed PMID: 28944070 (Four studies; moderate-quality evidence, mainly in hepatitis C cirrhosis.)
  7. — Tandon P, Garcia-Tsao G. "Bacterial infections, sepsis, and multiorgan failure in cirrhosis." Seminars in Liver Disease 2008. — PubMed PMID: 18293275 (Review of infection pathophysiology in cirrhosis and systemic consequences.)
  8. — European Association for the Study of the Liver. "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis." Journal of Hepatology 2018. — PubMed PMID: 29653741 (European Association for the Study of the Liver guidelines including SBP management recommendations.)
  9. — Runyon BA. "Management of adult patients with ascites due to cirrhosis." Hepatology 2004. — PubMed PMID: 14999706 (American Association for the Study of Liver Diseases practice guideline; criteria for SBP vs. secondary peritonitis and diagnostic paracentesis indications.)
  10. — Bernardi M et al. "Albumin in decompensated cirrhosis: new concepts and perspectives." Gut 2020. — PubMed PMID: 32102926 (Mechanism of albumin beyond volume expansion — LPS binding, anti-inflammatory effects.)
  11. — Follo A et al. "Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis." Hepatology 1994. — PubMed PMID: 7982650 (Natural history of AKI complicating SBP without albumin.)
  12. — Koulaouzidis A et al. "Leucocyte esterase reagent strips for the diagnosis of spontaneous bacterial peritonitis: a systematic review." European Journal of Gastroenterology & Hepatology 2008. — PubMed PMID: 19047835 (Seventeen studies, too heterogeneous to pool.)
  13. — Nousbaum JB et al. "Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis." Hepatology 2007. — PubMed PMID: 17464969 (Multicenter study of 2,123 paracenteses.)
  14. — Chinnock B et al. "Sensitivity of a bedside reagent strip for the detection of spontaneous bacterial peritonitis in ED patients with ascites." American Journal of Emergency Medicine 2019. — PubMed PMID: 30737002 (Emergency department cohort, 635 fluid analyses.)
  15. — Kim JJ et al. "Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis." American Journal of Gastroenterology 2014. — PubMed PMID: 25091061 (Two centers, 239 patients.)
  16. — Piano S et al. "The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial." Hepatology 2016. — PubMed PMID: 26084406 (Meropenem plus daptomycin vs. ceftazidime.)
  17. — Komolafe O et al. "Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis." Cochrane Database of Systematic Reviews 2020. — PubMed PMID: 31978256 (29 trials, 3,896 participants.)
  18. — Moreau R et al. "Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis." Gastroenterology 2018. — PubMed PMID: 30144431 (Double-blind trial, 291 patients.)
  19. — Mücke MM et al. "Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis." Clinical and Translational Gastroenterology 2020. — PubMed PMID: 32955202 (12 trials, 1,626 patients.)
  20. — Alhumaid S et al. "Proton pump inhibitors use and risk of developing spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis." Gut Pathogens 2021. — PubMed PMID: 33741033 (23 studies, 10,386 patients.)

Back to Table of Contents

Connections

Back to Table of Contents